Literature DB >> 22193376

Mild cognitive impairment in Parkinson's disease.

J G Goldman1, I Litvan.   

Abstract

Parkinson's disease (PD) traditionally has been defined by its characteristic motor hallmarks, but non-motor features such as cognitive impairment and dementia are increasingly recognized as part of PD. Mild cognitive impairment (MCI) is common in non-demented PD patients, occurring in about 20-50%. Frequency estimates and clinical features of mild cognitive impairment in PD (PD-MCI), however, vary across studies due to methodological differences and lack of uniform diagnostic criteria for PD-MCI. Overall, PD-MCI patients exhibit nonamnestic deficits in cognitive domains such as executive function, attention, and visuospatial function; however, the cognitive phenotype of PD-MCI is heterogeneous with some patients demonstrating greater amnestic deficits. PD-MCI patients, particularly those with posterior cortical profiles, may be at high risk for developing dementia. Various biomarkers studied in PD-MCI including cerebrospinal fluid, genetic analyses, and neuroimaging suggest that there may be distinct PD-MCI profiles. Future studies using uniform PD-MCI diagnostic criteria and incorporating biomarkers and longitudinal follow-up of PD-MCI cohorts are needed to understand PD-MCI as a transitional state between normal cognition and dementia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193376      PMCID: PMC3370887     

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  95 in total

1.  Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores.

Authors:  Eugenia Mamikonyan; Paul J Moberg; Andrew Siderowf; John E Duda; Tom Ten Have; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

2.  Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.

Authors:  Sarah Tomaszewski Farias; Dan Mungas; Bruce R Reed; Danielle Harvey; Charles DeCarli
Journal:  Arch Neurol       Date:  2009-09

3.  Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study.

Authors:  Flavio Nobili; Giovanni Abbruzzese; Silvia Morbelli; Roberta Marchese; Nicola Girtler; Barbara Dessi; Andrea Brugnolo; Cinzia Canepa; Giorgos Chr Drosos; Gianmario Sambuceti; Guido Rodriguez
Journal:  Mov Disord       Date:  2009-02-15       Impact factor: 10.338

4.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Authors:  S Hoops; S Nazem; A D Siderowf; J E Duda; S X Xie; M B Stern; D Weintraub
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

Review 5.  Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment.

Authors:  Jaime Kulisevsky; Javier Pagonabarraga
Journal:  Mov Disord       Date:  2009-06-15       Impact factor: 10.338

6.  The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.

Authors:  Caroline H Williams-Gray; Jonathan R Evans; An Goris; Thomas Foltynie; Maria Ban; Trevor W Robbins; Carol Brayne; Bhaskar S Kolachana; Daniel R Weinberger; Stephen J Sawcer; Roger A Barker
Journal:  Brain       Date:  2009-10-07       Impact factor: 13.501

7.  Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.

Authors:  Yaroslau Compta; María J Martí; Naroa Ibarretxe-Bilbao; Carme Junqué; Francesc Valldeoriola; Esteban Muñoz; Mario Ezquerra; Jose Ríos; Eduardo Tolosa
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

8.  Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

Authors:  Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R Williams
Journal:  Mov Disord       Date:  2009-01-30       Impact factor: 10.338

9.  Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

Authors:  Caroline H Williams-Gray; An Goris; Misuzu Saiki; Thomas Foltynie; D Alastair S Compston; Stephen J Sawcer; Roger A Barker
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

10.  Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment.

Authors:  Yoshiyuki Hosokai; Yoshiyuki Nishio; Kazumi Hirayama; Atsushi Takeda; Toshiyuki Ishioka; Yoichi Sawada; Kyoko Suzuki; Yasuto Itoyama; Shoki Takahashi; Hiroshi Fukuda; Etsuro Mori
Journal:  Mov Disord       Date:  2009-04-30       Impact factor: 10.338

View more
  58 in total

1.  DEVELOPMENT OF CLINICAL DEMENTIA RATING SCALE CUTOFF SCORES FOR PATIENTS WITH PARKINSON'S DISEASE.

Authors:  Kathryn A Wyman-Chick; B J Scott
Journal:  Mov Disord Clin Pract       Date:  2015-04-20

2.  Dopaminergic modulation of memory and affective processing in Parkinson depression.

Authors:  Lee X Blonder; John T Slevin; Richard J Kryscio; Catherine A Martin; Anders H Andersen; Charles D Smith; Frederick A Schmitt
Journal:  Psychiatry Res       Date:  2013-07-06       Impact factor: 3.222

3.  Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden; Bryan Bernard; Bichun Ouyang; Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

Review 4.  The spectrum of cognitive impairment in Lewy body diseases.

Authors:  Jennifer G Goldman; Caroline Williams-Gray; Roger A Barker; John E Duda; James E Galvin
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 5.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

6.  Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease.

Authors:  Lilah M Besser; Irene Litvan; Sarah E Monsell; Charles Mock; Sandra Weintraub; Xiao-Hua Zhou; Walter Kukull
Journal:  Parkinsonism Relat Disord       Date:  2016-04-09       Impact factor: 4.891

7.  Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial.

Authors:  Fabian J David; Julie A Robichaud; Sue E Leurgans; Cynthia Poon; Wendy M Kohrt; Jennifer G Goldman; Cynthia L Comella; David E Vaillancourt; Daniel M Corcos
Journal:  Mov Disord       Date:  2015-07-06       Impact factor: 10.338

8.  Elevated rates of mild cognitive impairment in HIV disease.

Authors:  David P Sheppard; Jennifer E Iudicello; Mark W Bondi; Katie L Doyle; Erin E Morgan; Paul J Massman; Paul E Gilbert; Steven Paul Woods
Journal:  J Neurovirol       Date:  2015-07-03       Impact factor: 2.643

9.  Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers.

Authors:  Eileen E Moran; Cuiling Wang; Mindy Katz; Laurie Ozelius; Alison Schwartz; Jelena Pavlovic; Roberto A Ortega; Richard B Lipton; Molly E Zimmerman; Rachel Saunders-Pullman
Journal:  Neurobiol Aging       Date:  2017-06-24       Impact factor: 4.673

10.  Implicit perceptual-motor skill learning in mild cognitive impairment and Parkinson's disease.

Authors:  Eric W Gobel; Kelsey Blomeke; Cindy Zadikoff; Tanya Simuni; Sandra Weintraub; Paul J Reber
Journal:  Neuropsychology       Date:  2013-05       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.